Ian Chan, CEO of Abpro discusses Covid-19 Treatments and the race to catch up to mutant variants

Ian Chan of Abpro, addresses the important conversation about Covid-19 treatments and the race to catch up to mutant variants.

The Boston based biotech Abpro Therapeutics is developing a monoclonal antibody treatment called ADP 300 that may be effective even in people infected with one of these new strains. This, according to pre-clinical data that the company published in nature communications.

You can find out more about Abpro by following the link here: https://abpro.com/

For more on this and related topics, visit www.trialsitenews.com to join the conversation!